Alverine

Identification

Name
Alverine
Accession Number
DB01616
Description

Alverine is a smooth muscle relaxant used to relieve cramps or spasms of the stomach and intestines. It is therefore useful in treating irritable bowel syndrome (IBS) and similar conditions. It can also be used to help relieve period pain.

Type
Small Molecule
Groups
Approved, Investigational
Structure
Thumb
Weight
Average: 281.4351
Monoisotopic: 281.214349869
Chemical Formula
C20H27N
Synonyms
  • Alverina
  • Alverine
  • Alverinum
  • Bis(gamma-phenylpropyl)ethylamine
  • Di(phenylpropyl)ethylamine
  • N-Ethyl-3-phenyl-N-(3-phenylpropyl)-1-propanamine
  • N-Ethyl-3,3'-diphenyldipropylamine
  • N-Ethyl-N-(3-phenylpropyl)benzenepropanamine
  • N,N-Bis(3-phenylpropyl)ethylamine
  • Phenopropamine
  • Phenpropamine

Pharmacology

Indication

Used to relieve cramps or spasms of the stomach and intestines. It is also useful in treating irritable bowel syndrome (IBS) and similar conditions. It can also be used to help relieve period pain. Alverine citrate is also under investigation to increase the cytotoxic effects of the proteasome inhibitor MG132 on breast cancer cells.

Contraindications & Blackbox Warnings
Learn about our commercial Contraindications & Blackbox Warnings data.
Learn More
Pharmacodynamics

Alverine is a smooth muscle relaxant. Smooth muscle is a type of muscle that is not under voluntary control; it is the muscle present in places such as the gut and uterus. Alverine acts directly on the muscle in the gut, causing it to relax. This prevents the muscle spasms which occur in the gut in conditions such as irritable bowel syndrome and diverticular disease. Diverticular disease is a condition in which small pouches form in the gut lining. These pouches can trap particles of food and become inflamed and painful. In irritable bowel syndrome the normal activity of the gut muscle is lost. The muscle spasms result in symptoms such as heartburn, abdominal pain and bloating, constipation or diarrhoea. By relaxing the gut muscle, alverine citrate relieves the symptoms of this condition. Alverine also relaxes the smooth muscle in the womb (uterus). It is therefore also used to treat painful menstruation, which is caused by muscle spasms in the uterus (dysmenorrhea).

Mechanism of action
TargetActionsOrganism
A5-hydroxytryptamine receptor 1A
antagonist
Humans
Absorption
Not Available
Volume of distribution
Not Available
Protein binding
Not Available
Metabolism

Rapidly converted to its primary active metabolite, which is then further converted to two secondary metabolites.

Route of elimination

High renal clearance of all metabolites indicating that they are eliminated by active renal secretion.

Half-life

The plasma half-life averages 0.8 hours for alverine and 5.7 hours for the active primary metabolite.

Clearance
Not Available
Adverse Effects
Learn about our commercial Adverse Effects data.
Learn More
Toxicity

Can produce hypotension and atropine-like toxic effects. Fatality has occurred following overdose with very high doses.

Affected organisms
  • Humans and other mammals
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
DrugInteraction
AcenocoumarolThe risk or severity of adverse effects can be increased when Alverine is combined with Acenocoumarol.
AcetazolamideThe risk or severity of adverse effects can be increased when Acetazolamide is combined with Alverine.
AcetophenazineThe risk or severity of adverse effects can be increased when Acetophenazine is combined with Alverine.
AclidiniumAlverine may increase the central nervous system depressant (CNS depressant) activities of Aclidinium.
AgomelatineThe risk or severity of adverse effects can be increased when Alverine is combined with Agomelatine.
AlfentanilThe risk or severity of adverse effects can be increased when Alfentanil is combined with Alverine.
AlimemazineThe risk or severity of adverse effects can be increased when Alimemazine is combined with Alverine.
AlmotriptanThe risk or severity of adverse effects can be increased when Almotriptan is combined with Alverine.
AlosetronThe risk or severity of adverse effects can be increased when Alosetron is combined with Alverine.
AlprazolamThe risk or severity of adverse effects can be increased when Alprazolam is combined with Alverine.
Additional Data Available
  • Extended Description
    Extended Description

    Extended description of the mechanism of action and particular properties of each drug interaction.

    Learn more
  • Severity
    Severity

    A severity rating for each drug interaction, from minor to major.

    Learn more
  • Evidence Level
    Evidence Level

    A rating for the strength of the evidence supporting each drug interaction.

    Learn more
  • Action
    Action

    An effect category for each drug interaction. Know how this interaction affects the subject drug.

    Learn more
Food Interactions
Not Available

Products

Product Ingredients
IngredientUNIICASInChI Key
Alverine citrate9JFB58YK1E5560-59-8RYHCACJBKCOBTJ-UHFFFAOYSA-N
International/Other Brands
Audmonal / Profenil / Spasmaverine / Spasmonal

Categories

ATC Codes
A03AX08 — AlverineA03AX58 — Alverine, combinations
Drug Categories
Chemical TaxonomyProvided by Classyfire
Description
This compound belongs to the class of organic compounds known as phenylpropylamines. These are compounds containing a phenylpropylamine moiety, which consists of a phenyl group substituted at the third carbon by an propan-1-amine.
Kingdom
Organic compounds
Super Class
Benzenoids
Class
Benzene and substituted derivatives
Sub Class
Phenylpropylamines
Direct Parent
Phenylpropylamines
Alternative Parents
Aralkylamines / Trialkylamines / Organopnictogen compounds / Hydrocarbon derivatives
Substituents
Amine / Aralkylamine / Aromatic homomonocyclic compound / Hydrocarbon derivative / Organic nitrogen compound / Organonitrogen compound / Organopnictogen compound / Phenylpropylamine / Tertiary aliphatic amine / Tertiary amine
Molecular Framework
Aromatic homomonocyclic compounds
External Descriptors
tertiary amine (CHEBI:518413)

Chemical Identifiers

UNII
46TIR1560O
CAS number
150-59-4
InChI Key
ZPFXAOWNKLFJDN-UHFFFAOYSA-N
InChI
InChI=1S/C20H27N/c1-2-21(17-9-15-19-11-5-3-6-12-19)18-10-16-20-13-7-4-8-14-20/h3-8,11-14H,2,9-10,15-18H2,1H3
IUPAC Name
ethylbis(3-phenylpropyl)amine
SMILES
CCN(CCCC1=CC=CC=C1)CCCC1=CC=CC=C1

References

General References
  1. Hayase M, Hashitani H, Suzuki H, Kohri K, Brading AF: Evolving mechanisms of action of alverine citrate on phasic smooth muscles. Br J Pharmacol. 2007 Dec;152(8):1228-38. Epub 2007 Oct 15. [PubMed:17934514]
  2. Wittmann T, Paradowski L, Ducrotte P, Bueno L, Andro Delestrain MC: Clinical trial: the efficacy of alverine citrate/simeticone combination on abdominal pain/discomfort in irritable bowel syndrome--a randomized, double-blind, placebo-controlled study. Aliment Pharmacol Ther. 2010 Mar;31(6):615-24. doi: 10.1111/j.1365-2036.2009.04216.x. Epub 2009 Dec 10. [PubMed:20003095]
  3. Ju D, Wang X, Xie Y: Dyclonine and alverine citrate enhance the cytotoxic effects of proteasome inhibitor MG132 on breast cancer cells. Int J Mol Med. 2009 Feb;23(2):205-9. [PubMed:19148544]
  4. Spasmonal Package Insert [Link]
Human Metabolome Database
HMDB0015554
KEGG Drug
D07440
PubChem Compound
3678
PubChem Substance
46506981
ChemSpider
3550
BindingDB
37636
RxNav
17627
ChEBI
518413
ChEMBL
CHEMBL253371
ZINC
ZINC000001481966
PharmGKB
PA164764505
Wikipedia
Alverine

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
4CompletedTreatmentIrritable Bowel Syndrome (IBS)3

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage Forms
FormRouteStrength
Capsule, liquid filledOral60 mg
Prices
Not Available
Patents
Not Available

Properties

State
Solid
Experimental Properties
PropertyValueSource
melting point (°C)< 25 °CPhysProp
boiling point (°C)212.5 °C at 1.30E+01 mm HgPhysProp
Predicted Properties
PropertyValueSource
Water Solubility0.00096 mg/mLALOGPS
logP5.73ALOGPS
logP5.46ChemAxon
logS-5.5ALOGPS
pKa (Strongest Basic)10.44ChemAxon
Physiological Charge1ChemAxon
Hydrogen Acceptor Count1ChemAxon
Hydrogen Donor Count0ChemAxon
Polar Surface Area3.24 Å2ChemAxon
Rotatable Bond Count9ChemAxon
Refractivity92.67 m3·mol-1ChemAxon
Polarizability35.42 Å3ChemAxon
Number of Rings2ChemAxon
Bioavailability1ChemAxon
Rule of FiveNoChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET Features
PropertyValueProbability
Human Intestinal Absorption+0.9925
Blood Brain Barrier+0.9482
Caco-2 permeable+0.8219
P-glycoprotein substrateSubstrate0.6368
P-glycoprotein inhibitor INon-inhibitor0.6741
P-glycoprotein inhibitor IINon-inhibitor0.853
Renal organic cation transporterInhibitor0.7848
CYP450 2C9 substrateNon-substrate0.7873
CYP450 2D6 substrateSubstrate0.5452
CYP450 3A4 substrateNon-substrate0.6521
CYP450 1A2 substrateInhibitor0.6458
CYP450 2C9 inhibitorNon-inhibitor0.9308
CYP450 2D6 inhibitorInhibitor0.8368
CYP450 2C19 inhibitorInhibitor0.5919
CYP450 3A4 inhibitorNon-inhibitor0.8074
CYP450 inhibitory promiscuityHigh CYP Inhibitory Promiscuity0.5739
Ames testNon AMES toxic0.9653
CarcinogenicityNon-carcinogens0.6473
BiodegradationNot ready biodegradable0.9649
Rat acute toxicity2.6539 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Strong inhibitor0.6077
hERG inhibition (predictor II)Inhibitor0.7442
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397)

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted GC-MS Spectrum - GC-MSPredicted GC-MSNot Available
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available

Targets

Kind
Protein
Organism
Humans
Pharmacological action
Yes
Actions
Antagonist
General Function
Serotonin receptor activity
Specific Function
G-protein coupled receptor for 5-hydroxytryptamine (serotonin). Also functions as a receptor for various drugs and psychoactive substances. Ligand binding causes a conformation change that triggers...
Gene Name
HTR1A
Uniprot ID
P08908
Uniprot Name
5-hydroxytryptamine receptor 1A
Molecular Weight
46106.335 Da
References
  1. Coelho AM, Jacob L, Fioramonti J, Bueno L: Rectal antinociceptive properties of alverine citrate are linked to antagonism at the 5-HT1A receptor subtype. J Pharm Pharmacol. 2001 Oct;53(10):1419-26. [PubMed:11697552]

Drug created on August 29, 2007 14:13 / Updated on June 12, 2020 10:51

Logo pink
Are you a
new drug developer?
Contact us to learn more about our customized products and solutions.
Logo pink
Stay in the know!
As part of our commitment to providing the most up-to-date drug information, we will be releasing #DrugBankUpdates with our newly added curated drug pages.
#DrugBankUpdates